Page 7 - Dr Reddy's Laboratories

Dr Reddy's Lab receives 3 observations for New York API manufacturing plant

The pharma firm said it will address all observations comprehensively within the stipulated timeline

Decoded: How Covid-19 vaccine efficacy helps to get an idea of protection

Efficacy of a vaccine means its ability to stimulate immunity in a person who has received the shot

Expert panel asks DRL to come back with more data on Sputnik safety

DRL applied for restricted emergency use of Sputnik V last week, has lined up 250 mn doses for Indians over next 12 months

Dr Reddy's applies for emergency use approval for Sputnik V vaccine

Aims to launch the vaccine in March if regulator approval comes through

Lupin plans expansion, aims to enter Chinese market in the next one year

The company has now decided to focus on specialty drugs. The annual price cuts made the Japanese generics market unattractive

Dr Reddy's reports Q3 profit of Rs 20 crore, revenues at Rs 4,930 crore

DRL said the Q3 results were impacted primarily due the non-recognition of deferred tax assets on impairment.

Dr Reddy's Laboratories likely to launch Sputnik V under EUA in March

The bridge trials on 1,600 participants in India was ongoing. The phase 2 trials are completed and the phase 3 is on.

Dr Reddy's, Zuventus get nod to conduct Covid-19 trials on repurposed drugs

NeuroRx and Relief Therapeutics have partnered to develop a drug called RLF-100 that has anti-inflammatory and anti-cytokine activity properties.

Select large caps likely to give good returns in 2021, say analysts

With valuations at a premium, brokerages highlight the need for caution

Russia to jointly produce Sputnik V vaccine for Covid with India: Envoy

Russian envoy to India Nikolay Kudashev on Monday said Moscow will jointly produce the Sputnik V vaccine for COVID-19 along with New Delhi

Pfizer moves US court against Aurobindo Pharma, Dr Reddy's on cancer drug

Pfizer Inc alleged that the drug makers were planning separately to come out with generic versions of its blockbuster multi-billion dollar drug Ibrance (palbociclib) before expiration of its patent

DCGI rejects DRL's proposal, denies full marketing rights for Remdesivir

Emergency use authorisation to continue; recently, WHO had raised doubts about efficacy of drug in treatment of Covid-19 patients

Dr Reddy's partners Dept of Biotech for vaccine clinical trials in India

Dr Reddy's Laboratories Ltd announced its partnership with BIRAC, DBT, for advisory support on clinical trials of Sputnik V vaccine in India

Dr Reddy's Q2 PAT down 30% to Rs 762 crore from Rs 1,092 cr year-ago

The PAT of Dr Reddys Laboratories for the quarter ended on September 30, 2020, was down by 30 per cent at Rs 762.3 crore compared to Rs 1,092.5 crore during the corresponding quarter last fiscal

USFDA approves Remdesivir as first Covid-19 therapy amid WHO reservations

Approval unlikely to increase prices immediately as Gilead has said licenses are royalty-free until the end of the health emergency

Dr Reddy's Labs isolates data centre services due to cyber attack

Dr Reddy's Laboratories on Thursday said it has isolated all data centre services following a cyber-attack

Dr Reddy's launches Famotidine generic product in US to treat acidity

Dr Reddy's Laboratories on Tuesday said it has launched over-the-counter (OTC) drug Famotidine tablets, used to treat gastroesophageal reflux disease, in the American market. The company has launched the product, which is equivalent to Johnson & Johnson's Pepcid AC, in the US after getting approval from the US Food and Drug Administration (USFDA), Dr Reddy's Laboratories said in a statement. Famotidine tablets are used to prevent and relieve heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain food and beverages. This launch will help us fulfil an important therapy gap created in antacids market due to Ranitidine withdrawal," Dr Reddy's Laboratories North America Generics CEO Marc Kikuchi said. The Pepcid AC brand and generic versions had US sales of around USD 211 million for the 12 months ended in August 2020.

Dr Reddy's gets DCGI nod to conduct Covid-19 vaccine phase 2/3 human trails

Dr Reddy's and Russian Direct Investment Fund on Saturday announced that they have received approval from DCGI to conduct an adaptive phase 2/3 human clinical trial for Sputnik V vaccine in India

Panel urges granting Dr Reddy's permission for Russia vaccine phase 2 trial

The SEC had on October 5 asked the firm to re-apply stating it will have to conduct both phase 2 and 3 clinical trials and cannot directly hold phase 3 trial for the vaccine in India

Dr Reddy's: Progress in Covid vaccine trials to boost firm's growth outlook

Good momentum in US and domestic sales, along with Covid-19 treatment portfolio is already driving analysts to upgrade earnings estimates